Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
by
Rotrosen, John
, Shulman, Matisyahu
, Weiss, Roger
, Costello, Elizabeth
, Nunes, Edward V.
, Novo, Patricia
in
Addictions
/ Alcohol use
/ Analgesics
/ Attrition
/ Buprenorphine
/ Care and treatment
/ Clinical research
/ Clinical trials
/ Cognitive behavioral therapy
/ Cognitive-behavioral factors
/ Contingency learning
/ Counseling
/ Detoxification
/ Detoxification (Substance abuse treatment)
/ Discontinued
/ Disorders
/ Dropping out
/ Drug abuse
/ Drug dosages
/ Drug overdose
/ Drug therapy
/ Drug use
/ Drugs
/ FDA approval
/ Health Psychology
/ Long term
/ Longitudinal studies
/ Medical research
/ Medical treatment
/ Medicine
/ Medicine & Public Health
/ Medicine, Experimental
/ Methadone
/ Naloxone
/ Naltrexone
/ Narcotics
/ National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum: 20 Years of Research Informing Practice
/ Opioid use disorder
/ Opioids
/ Patients
/ Pharmacology
/ Pharmacology/Toxicology
/ Product development
/ Psychopharmacology
/ Public Health
/ Recovery
/ Rehabilitation
/ Relapse
/ Remission (Medicine)
/ Retention
/ Review
/ Social Work
/ Strategies
/ Substance abuse treatment
/ Substance use disorder
/ Therapy
/ Treatment outcomes
/ Young adults
2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
by
Rotrosen, John
, Shulman, Matisyahu
, Weiss, Roger
, Costello, Elizabeth
, Nunes, Edward V.
, Novo, Patricia
in
Addictions
/ Alcohol use
/ Analgesics
/ Attrition
/ Buprenorphine
/ Care and treatment
/ Clinical research
/ Clinical trials
/ Cognitive behavioral therapy
/ Cognitive-behavioral factors
/ Contingency learning
/ Counseling
/ Detoxification
/ Detoxification (Substance abuse treatment)
/ Discontinued
/ Disorders
/ Dropping out
/ Drug abuse
/ Drug dosages
/ Drug overdose
/ Drug therapy
/ Drug use
/ Drugs
/ FDA approval
/ Health Psychology
/ Long term
/ Longitudinal studies
/ Medical research
/ Medical treatment
/ Medicine
/ Medicine & Public Health
/ Medicine, Experimental
/ Methadone
/ Naloxone
/ Naltrexone
/ Narcotics
/ National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum: 20 Years of Research Informing Practice
/ Opioid use disorder
/ Opioids
/ Patients
/ Pharmacology
/ Pharmacology/Toxicology
/ Product development
/ Psychopharmacology
/ Public Health
/ Recovery
/ Rehabilitation
/ Relapse
/ Remission (Medicine)
/ Retention
/ Review
/ Social Work
/ Strategies
/ Substance abuse treatment
/ Substance use disorder
/ Therapy
/ Treatment outcomes
/ Young adults
2021
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
by
Rotrosen, John
, Shulman, Matisyahu
, Weiss, Roger
, Costello, Elizabeth
, Nunes, Edward V.
, Novo, Patricia
in
Addictions
/ Alcohol use
/ Analgesics
/ Attrition
/ Buprenorphine
/ Care and treatment
/ Clinical research
/ Clinical trials
/ Cognitive behavioral therapy
/ Cognitive-behavioral factors
/ Contingency learning
/ Counseling
/ Detoxification
/ Detoxification (Substance abuse treatment)
/ Discontinued
/ Disorders
/ Dropping out
/ Drug abuse
/ Drug dosages
/ Drug overdose
/ Drug therapy
/ Drug use
/ Drugs
/ FDA approval
/ Health Psychology
/ Long term
/ Longitudinal studies
/ Medical research
/ Medical treatment
/ Medicine
/ Medicine & Public Health
/ Medicine, Experimental
/ Methadone
/ Naloxone
/ Naltrexone
/ Narcotics
/ National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum: 20 Years of Research Informing Practice
/ Opioid use disorder
/ Opioids
/ Patients
/ Pharmacology
/ Pharmacology/Toxicology
/ Product development
/ Psychopharmacology
/ Public Health
/ Recovery
/ Rehabilitation
/ Relapse
/ Remission (Medicine)
/ Retention
/ Review
/ Social Work
/ Strategies
/ Substance abuse treatment
/ Substance use disorder
/ Therapy
/ Treatment outcomes
/ Young adults
2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
Journal Article
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”
2021
Request Book From Autostore
and Choose the Collection Method
Overview
Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications—methadone, buprenorphine, and extended-release injectable naltrexone,— are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited, in part due to poor rates of retention in treatment. In addition, minimum recovery milestones and other factors that influence when and whether individuals can safely discontinue medications are unknown. The National Drug Abuse Treatment Clinical Trials Network (CTN) study “Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy” (RDD; CTN-0100) will be among the largest clinical trials on treatment of OUD yet conducted, consisting of two phases, the Retention phase, and the Duration-Discontinuation phase. The Retention phase, open to patients initiating treatment, will test different doses and formulations of buprenorphine (standard dose sublingual, high dose sublingual, or extended-release injection), and a digital therapeutic app delivering contingency management and cognitive behavioral counseling on the primary outcome of retention in treatment. The Discontinuation phase, open to patients in stable remission from OUD and choosing to discontinue medication (including participants from the Retention phase or from the population of patients treated at the clinical site, referred by an outside prescriber or self-referred) will study different tapering strategies for buprenorphine (sublingual taper vs taper with injection buprenorphine), and a digital therapeutic app which provides resources to promote recovery, on the primary outcome of relapse-free discontinuation of medication. This paper describes how the RDD trial derives from two decades of research in the CTN. Initial trials (CTN-0001; CTN-0002; CTN-0003) focused on opioid detoxification, showing buprenorphine-naloxone was effective for detoxification, but that acute detoxification did not appear to be an effective treatment strategy. Trials on comparative effectiveness of medications for opioid use disorder (MOUD) (CTN-0027; CTN-0030; and CTN-0051) highlighted the problem of dropout from treatment and few trials defined retention on MOUD as the primary outcome. Long-term follow-up studies on those patient samples demonstrated the importance of long-term continuation of medication for many patients to sustain remission. Overall, these trials highlight the potential of a stable research infrastructure such as CTN to advance treatment effectiveness through a programmatic succession of large clinical trials.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
This website uses cookies to ensure you get the best experience on our website.